Our study showed that the methylation degree of 10 out of 32 CpG sites in the CDH1 gene promotor/exon1 regions is significantly increased in cisplatin-resistant ovarian cancer cells line A2780cis compared with sensitive A2780 cells. This evidence concerns the gene CDH1 and ovarian cancer.